Načítá se...
Targeted therapy of chronic myeloid leukemia
Inhibition of BCR-ABL with kinase inhibitors has become a well-accepted strategy for targeted therapy of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML), and has been shown to be highly effective in controlling the disease. However, BCR-ABL kinase inhibitors do not efficiently kill leuk...
Uloženo v:
| Vydáno v: | Biochem Pharmacol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2010
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4440481/ https://ncbi.nlm.nih.gov/pubmed/20470758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.05.001 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|